ArticleJournal of family medicine and primary care2025
Orbital mucormycosis post-COVID-19: Demographics, clinical features, and treatment outcomes.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the demographic profile, risk factors, clinical manifestations, and treatment outcomes of patients with orbital mucormycosis in the post-COVID-19 context. Methodology: Retrospective analysis was conducted on the medical records of patients diagnosed with biopsy proven orbital mucormycosis following a confirmed or suspected history of COVID-19 infection. Data regarding demographic features, personal profile, COVID-19 status, ocular manifestations, radiological findings, treatment modalities, and outcomes were collected and analyzed. Results: Among the 14 patients in the study, the duration between COVID-19 onset and mucormycosis onset was 14.1 days on average. Comorbidities, particularly diabetes mellitus and hypertension, were prevalent among both COVID-19-positive and COVID-19-negative patients. Ocular manifestations at presentation included pain (80%), lid edema (100%), restricted extraocular movements (86.67%), and proptosis (53.33%). Ethmoid sinus involvement was most common (33.34%), along with pterygopalatine and inferior orbital fissure involvement (66.67%). Sinus debridement was the primary treatment modality (93.34%), with transcutaneous retrobulbar amphotericin B (TRAM-B) used in 46.67% of cases. Among 14 patients, 80% achieved globe salvage, while 40% had improved visual acuity and motility. Significant prognostic factors included intracranial extension and ICU admission. Conclusion: Aggressive surgical and antifungal management, supported by a multidisciplinary approach, improves outcomes in this life-threatening condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.